Equine Influenza

Equine Influenza

Horses

Equine Influenza

Clinical Signs

The signs of equine influenza usually start suddenly, with an affected horse abruptly developing a high fever. A dry, harsh cough begins early in the infection and may last for weeks. The nasal discharge initially is watery and scant, but usually becomes yellow and heavy, due to secondary bacterial infection. A sick horse may have watery eyes, enlarged lymph nodes between the mandibles, edema and stiffness in the legs, and breathing difficulty. Depression, weakness, and loss of appetite are common. Horses with relatively mild cases of equine influenza usually recover in a week or so, but severely ill horses may require weeks to months to recover fully, especially if they are not allowed to rest completely. Most uncomplicated cases recover fully, but affected animals under stress, or ones not allowed to rest, may develop secondary pneumonia, a chronic cough, or inflammation of the heart muscle, sometimes resulting in death.

Merck Animal Health Solutions

ProductDescription
PRESTIGE V+VEE WITH HAVLOGENA combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin, Eastern, Western, and Venezuelan Equine Encephalomyelitis Virus, Equine Herpesvirus EHV-1 and EHV-4, Equine Influenza Virus subtype A2 including KY 93 strain and Tetanus Toxoid.
PRESTIGE V WITH HAVLOGENA combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin, Equine Encephalomyelitis Virus, Eastern and Western, Equine Herpesvirus EHV-1 and EHV-4. Equine Influenza Virus subtype A2 including KY 93 strain and Tetanus Toxoid.
PRESTIGE II WITH HAVLOGENA combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin, Equine Herpesvirus EHV-1 and EHV-4 and Equine Influenza Virus subtype A2 including KY 93 strain.
FLU AVERT I.N. VACCINEFlu Avert® I.N. vaccine is a unique, proprietary, intranasal, modified-live equine influenza vaccine proven by challenge studies to be safe and effective against North American and Eurasian strains of the equine influenza virus.
ENCEVAC TC-4+VEE WITH HAVLOGENA combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin, Eastern, Western and Venezuelan Equine Encephalomyelitis Viruses, Equine Influenza Virus subtypes A2 including KY 93, KY 02, and NM2/93 strains, and Tetanus Toxoid. Merck Animal Health serological data suggest cross protection against certain U.S. and European strains, including Kentucky 91, 93, 99, 02, Ohio 03, Newmarket1/93, Newmarket 2/93, Suffolk 89, and South Africa 03.
ENCEVAC TC-4 WITH HAVLOGENA combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin, Eastern and Western Equine Encephalomyelitis Viruses, Equine Influenza Virus subtypes A2 including KY 93, KY 02, and NM2/93 strains, and Tetanus Toxoid. Merck Animal Health serological data suggest cross protection against certain U.S. and European strains, including Kentucky 91, 93, 99, 02, Ohio 03, Newmarket1/93, Newmarket 2/93, Suffolk 89, and South Africa 03.
TRUSTe European Safe Harbor certification
Validate TRUSTe privacy certification